On February 3, 2021 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, reported the pricing of an underwritten public offering of an aggregate of 14,273,684 shares of common stock at a public offering price of $4.75 per share (Press release, Moleculin, FEB 3, 2021, View Source [SID1234574550]). Moleculin has granted the underwriters a 30-day option to purchase up to an additional 2,141,052 shares of common stock offered in the public offering. The offering is expected to close on or about February 5, 2021, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. (PRNewsfoto/Moleculin Biotech, Inc.)

The gross proceeds of the offering are expected to be $67.8 million, prior to deducting the underwriting discount and other estimated offering expenses but excluding any exercise of the underwriters’ option. The Company intends to use the net proceeds of the offering to fund its planned clinical trials, preclinical programs, for other research and development activities and for general corporate purposes.

Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering and Roth Capital Partners, LLC is acting as the co-manager for the offering. Maxim Group LLC is acting as financial advisor to the Company.

The securities described above are being offered by the Company pursuant to a shelf registration statement on Form S-3 (No. 333-235686) originally filed December 23, 2019 with the Securities and Exchange Commission (SEC) and declared effective by the SEC on April 9, 2020. A final prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at View Source Copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at (212) 667-8055, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On February 3, 2021 GlaxoSmithKline reported that Strong growth of new and specialty products; on track to deliver two exciting new companies (Press release, GlaxoSmithKline, FEB 3, 2021, View Source [SID1234574532])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Strong sales performance from key growth drivers in HIV, Respiratory, Oncology and Consumer Healthcare offset disruption from COVID-19 to adult vaccinations
Pharmaceuticals £17 billion -3% AER, -1% CER; new and specialty products £9.7 billion +11% AER, +12% CER
Vaccines £7 billion -2% AER, -1% CER. Shingrix £2 billion +10% AER, +11% CER
Consumer Healthcare £10 billion +12% AER, +14% CER (pro-forma -2% CER*)
New Biopharma product portfolio strengthened with 9 approvals in 2020 and Cabenuva in the US in January 2021
Effective cost control supports delivery of adjusted earnings per share in line with FY 2020 guidance
Total Group operating margin 22.8%. Total EPS 115.5p +23% AER, +26% CER
Adjusted Group operating margin 26.1%. Adjusted EPS 115.9p -6% AER, -4% CER
Q4 net cash flow from operations £4 billion. Free cash flow £3 billion
Significant progress on Biopharma pipeline with over 20 assets now in late-stage clinical trials
20+ new product launches planned by 2026, 10+ with potential peak annual revenues in excess of $1 billion
Pivotal study starts/data expected in 2021 for RSV vaccine in older adults, COVID-19 assets, long-acting anti IL-5 antagonist, daprodustat and dostarlimab
Oncology momentum building: 15 potential medicines in trials, including 9 immuno-oncology and 3 cell therapies
20+ deals executed, including acquisitions of new antibody, mRNA and genetics/genomics technologies
On track for separation into new standalone Biopharma and Consumer Healthcare companies in 2022
2020 targets met with £0.3 billion annual cost savings and £1.1 billion divestment proceeds achieved
Biopharma investor update in June to set out progress on innovation, commercial execution and growth outlook together with capital allocation priorities
Sustained progress and leadership in ESG
Sector leading in key indices, including DJSI and Sustainalytics, and #1 rank in 2021 Access to Medicines Index
New environmental targets set to achieve net zero impact on climate and net positive impact on nature by 2030
2021 Adjusted EPS expected to decline by a mid to high-single digit percentage in CER
Reflects further growth in new and specialty products and Consumer Healthcare, increased investment in our pipeline and deferral of strong growth in Vaccines performance due to impact of COVID-19 immunisation programmes
2022 outlook remains unchanged. Continue to expect meaningful improvement in revenues and margins
Dividend of 23p/share declared for Q4 2020; 80p/share for FY 2020. Expected dividend of 80p/share for FY 2021
Distribution policy for new GSK to be implemented in 2022 to support growth and investment. Aggregate distributions expected to be lower than at present
Emma Walmsley, Chief Executive Officer, GSK said:
"2020 was an extraordinary year for all of us, and one of significant ogress for GSK. We invested in our pipeline and new launches, readied the company for separation, and had to rapidly mobilise and respond to the pandemic. I am extremely proud of the agility and resilience our teams have shown. We delivered our guidance for the year, offsetting the significant impact of COVID-19 on adult vaccinations, with strong performances of new products and effective cost control.

"Importantly, progress against our strategic goals remains firmly on track. We are building a high value biopharma pipeline, have substantially integrated our Consumer JV and have delivered all our first year targets for our two year separation programme. This means we are in a strong position to launch new competitive, standalone Biopharma and Consumer healthcare companies in 2022. In doing so, we have high confidence that we can achieve meaningful global impact to health and significant value creation for shareholders."

On February 3, 2021 The Canadian Glycomics Network (GlycoNet) reported $1.3 million in funding to 11 glycomics research projects (Press release, GlycoNet, FEB 3, 2021, View Source;utm_medium=rss&utm_campaign=new-glycomics-research-investments-from-glyconet-to-facilitate-a-resilient-recovery-for-canada [SID1234574551]). The investment is being leveraged through GlycoNet’s four funding streams—Collaborative Team, Strategic Initiative, Translational, and Clinical Partnerships—which aim to foster health innovations by gaining more understanding of the role of sugars in health and diseases. Industry collaborators, health foundations, and business partners are also co-investing $2.6 million for nearly $4 million in total funding towards areas of cancer, chronic diseases, infectious diseases, and neurodegenerative diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Part of this funding will support the development of an AAV9 gene therapy that is currently being developed by Dr. Jagdeep Walia from Queen’s University, in collaboration with Taysha Gene Therapies. Walia and his research team will conduct preclinical studies to test the safety and efficacy of the gene therapy when delivered intrathecally, with the intent of treating children with GM2A deficiency in clinical studies in the future.

Today’s announcement also includes funding for a team of researchers at the University of British Columbia (UBC) to develop enzymatic tools that will convert A and B type blood to the universal donor O type blood. The UBC researchers, led by Dr. Stephen Withers, will collaborate with the Canadian Blood Services and ABOzymes Biomedical to fully assess the efficacy of the enzymes, as well as the safety and compatibility of the converted blood. This project will help Canada build a strong foundation of sustainable national blood supplies and develop life-saving protocols for those who need blood transfusion in emergency situations.

Further, this funding will support the pilot project by McGill researcher, Dr. Donald Sheppard, and University of Alberta researcher, Dr. Todd Lowary to transform biomedicine for personalized antifungal therapies. In collaboration with Atara Biotherapeutics and Dr. Michel Sadelain, Director of the Center for Cell Engineering at Memorial Sloan Kettering Cancer Center, the research team will employ CAR T-cells technology to develop tools to treat invasive fungal infections that cause chronic lung diseases in patients undergoing chemotherapy and transplantation.

"As we navigate post-pandemic economic and social recovery, investments in science and innovations are essential to bring resilience and prosperity to our communities," said Dr. Warren Wakarchuk, Scientific Director of GlycoNet. "GlycoNet is proud to work with industry partners and cross-sectoral collaborators to drive glycomics research that will bring game-changing solutions to the future of Canadian healthcare and bioeconomy."

Glycomics research collaborations help Canada harness the potential of bio-innovations to build more self-reliant, sustainable, and prosperous communities. Through mobilizing knowledge and expertise in the study of carbohydrates, along with targeted investments to form strategic alliance among academic institutions, industry, and business partners, this funding will enable researchers to create homegrown solutions to power Canada to adapt to complex health challenges and build a resilient bioeconomy.

Quotes
"As we navigate post-pandemic economic and social recovery, investments in science and innovations are essential to bring resilience and prosperity to our communities. GlycoNet is proud to work with industry partners and cross-sectoral collaborators to drive glycomics research that will bring game-changing solutions to the future of Canadian healthcare and bioeconomy." – Warren Wakarchuk, Scientific Director, GlycoNet

"Many countries in the world have an imbalance between the ABO groups of those donating blood and the ABO groups of transfused blood. This is primarily because of an increased use of O blood when the blood group of the patient is not known. This can lead to blood shortages of group O blood. The technology developed by Dr. Withers allows for a possible solution to this problem by converting group A blood to group O to rebalance blood centre inventories." – Dr. Dana Devine, Chief Scientist, Canadian Blood Services

Quick Facts
Today’s announcement is for $1.3 million in funding for glycomics research and an additional $2.6 million in co-funding from research partners and industry collaborators across Canada.
This funding will support four new projects within GlycoNet’s Collaborative Team Grant, one Clinical Partnership Grant, five Strategic Initiatives Grant, and one Translational Grant.
Since 2015, GlycoNet has leveraged $24.2 million from the federal NCE program into a total investment of $49.7 million in R&D, supported the training of over 450 highly qualified personnel and spun-out five new Canadian companies.

On February 3, 2021 Argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, reported that the pricing of a global offering of ordinary shares represented by American Depository Shares (ADSs) in the United States and certain other countries outside of European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area and the United Kingdom (Press release, argenx, FEB 3, 2021, View Source [SID1234574568]). The Company anticipates total gross proceeds of approximately $1.0 billion (approximately €830.3 million) from the sale of 1,608,000 ADSs at a price of $320.00 per ADS and the sale of 1,517,000 ordinary shares at a price of €265.69 per ordinary share. Each of the ADSs offered in the offering represents the right to receive one ordinary share, nominal value of €0.10 per share. The U.S. offering and the European private placement are currently expected to close simultaneously on February 5, 2021, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, argenx has granted the underwriters of the offering a 30-day option to purchase up to 468,750 ordinary shares (which may be represented by ADSs) on the same terms and conditions.

argenx’s ADSs are currently listed on the Nasdaq Global Select Market under the symbol "ARGX," and argenx’s ordinary shares are currently listed on Euronext Brussels under the symbol "ARGX."

J.P. Morgan, Morgan Stanley, BofA Securities and Cowen are acting as joint bookrunning managers for the offering.

The securities are being offered in the United States pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC). A preliminary prospectus supplement relating to the securities was filed with the SEC on February 1, 2021. The final prospectus supplement relating to the securities will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the U.S. offering may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at [email protected]; from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus Department, by email at [email protected], or by telephone at (866) 718-1649; from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, North Carolina 28255-0001, Attn: Prospectus Department, or by email at [email protected]; or from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at [email protected], or by telephone at (833) 297-2926.

A request for the admission to listing and trading of the ordinary shares (including the ordinary shares underlying the ADSs) on the regulated market of Euronext Brussels will be made.

This press release is for information purposes only and does not constitute, and should not be construed as, an offer to sell or the solicitation of an offer to buy or subscribe to any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale is not permitted or to any person or entity to whom it is unlawful to make such offer, solicitation or sale. Reference is also made to the restrictions set out in "Important information" below. This press release is not for publication or distribution, directly or indirectly, in or into any state or jurisdiction into which doing so would be unlawful or where a prior registration or approval is required for such purpose.

On February 3, 2021 DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, reported that it is commencing an underwritten public offering of its common stock (the "Offering") (Press release, DURECT, FEB 3, 2021, https://www.prnewswire.com/news-releases/durect-corporation-announces-proposed-offering-of-common-stock-301221648.html [SID1234574585]). All of the shares to be sold in the Offering will be sold by DURECT, subject to customary closing conditions. In addition, DURECT intends to grant the underwriter for the Offering a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Fitzgerald & Co. is acting as the sole book running manager for the Offering.

The Offering is being made pursuant to a "shelf" registration statement on Form S-3 (File No. 333-226518) previously filed by DURECT with the Securities and Exchange Commission (the "SEC") on September 28, 2019 and declared effective by the SEC on October 9, 2018. The Offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement relating to, and describing the terms of, the Offering will be filed with the SEC. Before you invest, you should read the registration statement, the preliminary prospectus, the documents that DURECT has filed with the SEC that are incorporated by reference into the registration statement, and the other documents DURECT has filed with the SEC for more complete information about DURECT and the offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the Offering can be obtained, when available, from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th floor, New York, NY 10022; Email: [email protected]. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.